Metabolism and Endocrine Disorders: What Wnt Wrong?

Abstract

A fundamental question in cell biology underlies how nutrients are regenerated to maintain and renew tissues. Physiologically, the canonical Wnt signaling is a vital pathway for cell growth, tissue remodeling, and organ formation; pathologically, Wnt signaling contributes to the development of myriad human diseases such as cancer. Despite being the focus of intense research, how Wnt intersects with the metabolic networks to promote tissue growth and remodeling has remained mysterious. Our understanding of metabolism has been revolutionized by technological advances in the fields of chemical biology, metabolomics, and live microscopy that have now made it possible to visualize and manipulate metabolism in living cells and tissues. The application of these toolsets to innovative model systems have propelled the Wnt field into new realms at the forefront answering the most pressing paradigms of cell metabolism in health and disease states. Elucidating the basis of Wnt signaling and metabolism in a cell-type and tissue-specific manner will provide a powerful base of knowledge for both basic biomedical fields and clinician scientists, and has the promise to generate new, transformative therapies in disease and even processes of aging.

Simplifying the B Complex: How Vitamins B6 and B9 Modulate One Carbon Metabolism in Cancer and Beyond

“…The DHFR enzyme is the target of MTX, the first antimetabolite therapeutic that was initially developed for the treatment of acute lymphoblastic leukemia (ALL) [ 58 ]. The success of MTX-based interventions gave rise to a series of antifolate cancer therapies such as 5-fluorouracil (5-FU) [ 223 ], which targets TS in the folate cycle. MTX has been prominently used to treat psoriasis, rheumatoid arthritis, and several cancers [ 72 , 224 , 225 ].…”

Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy

“…Upon secretion, extracellular sclerostin binds to the Wnt receptor, low-density lipoprotein receptor-related protein (LRP5/6), and occludes the Wnt ligand binding sites that are required to initiate Wnt signaling and β-catenin transcriptional activity [15][16][17][18]. Among the many secreted Wnt inhibitors, sclerostin is a favorable candidate for drug design as it is primarily expressed in bone [19]. In fact, loss-of-function mutations in the sclerostin encoding gene, SOST, result in sclerosteosis and van Buchem disease (VBD), two autosomal recessive disorders that are characterized by hyperactive osteoblasts, high bone mass, and a thickening of the cortical bone [20,21].…”